This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

JAMA. 2000;284:1640.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The FDA has approved budesonide inhalation suspension (Pulmicort Respules, AstraZeneca Group, Wayne, Pa) as maintenance and prophylactic therapy for asthma in children aged 1 to 8 years. The product, a sterile suspension for inhalation via jet nebulizer, contains the first anti-inflammatory corticosteroid approved for inhalation in children younger than 4 years.

Approval of the micronized budesonide inhalation suspension was based on three double-blind, placebo-controlled, randomized clinical trials of 12 weeks duration. The analysis included 946 patients who were aged 1 to 8 years and had persistent asthma.

The studies showed that when used once or twice per day, up to a total dosage of 1 mg/d, the product significantly decreased asthma symptom scores across sex and age groups and significantly reduced the need for bronchodilator therapy. A reduction of 0.28 to 0.57 on a scale of 0-3 in nighttime and daytime symptom scores of asthma was observed within 2 to . . . [Full Text of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?